Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

CAPSULE SUMMARY: We characterise the immunopathogenesis of autoinflammation, HLH, and early onset intestinal inflammation caused by homozygous mutation in DNASE2, and provide the first description of favourable therapeutic response to JAK1/JAK2 blockade in this disease.

Original publication

DOI

10.1016/j.jaci.2019.11.020

Type

Journal article

Journal

J Allergy Clin Immunol

Publication Date

24/11/2019

Keywords

DNASE2 deficiency, JAK inhibition, Type I Interferon, autoinflammation, baricitinib, early-onset intestinal inflammation, haemophagocytic lymphohistiocytosis